Cincinnati-based Medpace, a global contract research organization (CRO), has hired Yong-Xi Li as Executive Director of its new Medpace Bioanalytical Laboratories. This new laboratory is projected to open in fall of 2008 and will complement services provided by other Medpace research facilities, such as Medpace Clinical Pharmacology and Medpace Reference Laboratories.

Dr. Li joins Medpace with a strong background in bioanalytical technology, method development, validation, and sample analysis in support of pharmaceutical development and both preclinical and clinical studies.

At Medpace, Dr. Li will direct operations and activities of the new, advanced mass spectrometry Medpace Bioanalytical Laboratories, including bioanalytical aspects for small and large drug molecules according to GLP and GMP compliances and ICH guidelines.

Dr. Li comes to Medpace from Eurofins Scientific, NJ, where he served as Senior Director, managing its laboratory process and facilitating bioanalytical technology and methods. Prior to his work at Eurofins Scientific, Dr. Li was the Vice President of Ricerca and then the Vice President of XenoBiotics Laboratories, where he led and expanded the bioanalytical laboratories and activities.

Dr. Li arrived in the United States and worked as a senior research scientist under Dr. K.J. Klubende and Dr. B.H. Davis to establish his first bioanalytical laboratory. He went on to do postdoctoral studies in Chemistry at Cornell University, Baker Laboratory, in Ithaca, New York.

“We are excited to have an experienced chemist such as Yong-Xi Li on staff,” said August Troendle, M.D., Medpace’s CEO.